猪β-干扰素的原核表达及其对猪流行性腹泻病毒的抑制作用研究

本研究通过PCR技术克隆了猪β干扰素全基因,设计引物亚克隆猪β干扰素成熟蛋白编码基因并对,5’端1个稀有密码子进行了大肠杆菌偏嗜性改造。构建了猪IFN-β原核单纯表达载体pRLC-poIFNβ,实现了poIFN-β在大肠杆菌中的表达,表达产物约占菌体总蛋白的17.3%。表达产物以包涵体形式存在,用含6mol/L盐酸胍的变性液溶解及含GSH-GSSG复性液复性处理,复性后的表达产物经凝胶层析纯化后,MDBK细胞-VSV病变抑制法测定结果表明,重组猪β干扰素具有良好的抗病毒活性,约为5.6x105U/mg。用重组猪β干扰素处理猪肾传代细胞PK-15后,细胞病变抑制法(CPE50)测定结果表明:重组猪β干扰素可显著抑制猪流行性腹泻病毒(PEDV)的感染。     

猪β-干扰素的原核表达及其对猪流行性腹泻病毒的抑制作用研究

本研究通过PCR技术克隆了猪β干扰素全基因,设计引物亚克隆猪β干扰素成熟蛋白编码基因并对,5'端1个稀有密码子进行了大肠杆菌偏嗜性改造.构建了猪IFN-β原核单纯表达载体pRLC-poIFNβ,实现了poIFN-β在大肠杆菌中的表达,表达产物约占菌体总蛋白的17.3%.表达产物以包涵体形式存在,用含6mol/L盐酸胍的变性液溶解及含GSH-GSSG复性液复性处理,复性后的表达产物经凝胶层析纯化后,MDBK细胞-VSV病变抑制法测定结果表明,重组猪β干扰素具有良好的抗病毒活性,约为5.6x105U/mg.用重组猪β干扰素处理猪肾传代细胞PK-15后,细胞病变抑制法(CPE50)测定结果表明重组猪β干扰素可显著抑制猪流行性腹泻病毒(PEDV)的感染.     

人EGF受体L2结构域在大肠杆菌中表达、包涵体柱上复性及纯化

以PCR方法从克隆的EGFR胞外区cDNA中扩增编码EGFR-L2结构域的DNA片段,在其3′端加入编码His6标签的序列,与pET-3c连接构建EGFR-L2原核表达载体。该蛋白在大肠杆菌BL21(DE3)中获得高效表达,免疫印迹分析表明表达产物全部以包涵体形式存在,分步透析法和稀释法都不能获得可溶性复性产物,而Ni²⁺-NTA柱上复性法不仅能够获得可溶性的EGFR-L2蛋白,而且产物同时得到高度纯化,纯度>95％,复性的EGFR-L2与其配基EGF具有特异性的结合活性,但亲和力较低。这表明His6标签不但便于纯化目标蛋白,而且可利用Ni²⁺-NTA柱进行柱上复性,适用于不易通过常规方法复性的重组蛋白的制备。     

草鱼胰岛素样生长因子-Ⅰ基因在大肠杆菌中的表达

 为构建草鱼 (Ctenopharyngodonidellus )胰岛素样生长因子 Ⅰ (IGF Ⅰ )大肠杆菌表达质粒 ,对已克隆到的草鱼IGF Ⅰ基因进行改造 .改造后的基因去除了原cDNA的信号肽和E区序列 ,并在基因的两端分别加入起始密码子和终止密码子 .将改造后的编码草鱼IGF Ⅰ成熟肽基因亚克隆到pBV 2 2 0中 ,构建成表达质粒pBVgIGF7.转化大肠杆菌 (Escherichiacoli)进行表达 .SDS PAGE显示 ,含重组表达质粒的菌株经热诱导后表达出一约 7 5kD的特异蛋白 .表达量占菌体总蛋白的2 0 0 3% ,表达产物主要以包涵体形式存在 .重组蛋白经纯化和复性后 ,采用MTT法测定其对草鱼吻端成纤维细胞PSF和草鱼卵巢细胞CO的促增殖作用 .结果表明 ,所获得的重组草鱼IGF Ⅰ具有生物活性     

重组猪a干扰素基因定点突变及在大肠杆菌中的表达

用巨引物PCR法介导的定点突变把猪α干扰素(PoIFN-α)第86位Cys(TGC)突变为Tyr(TAC),同时将其成熟蛋白N端第一个密码子TGT同义突变大肠杆菌偏爱的密码子TGC,构建了大肠杆菌融合基因表达载体pGEX-IFN,表达产物占菌体总蛋白的20%.将以包涵体形式表达的目的蛋白经变、复性处理,并以FPLC进一步纯化,得到了具有较高生物活性的产物(5200IU/mg).     

人干扰素和脑啡肽融合蛋白的表达和生物学活性

以INFα-m基因为模版,采用overlapping PCR技术构建甲硫氨酸脑啡肽干扰素表达质粒pBV220/Enk-/Met-INFα-m,转化大肠杆菌DH5α表达,产物以包涵体形式存在.包涵体经分离、变性、复性,然后经CM-Sepharose-FF、DEAE-Sepharose-FF离子交换层析和Sephacryal-HR100分子筛纯化,获得较纯的Enk-IFNα-m融合蛋白.生物活性检测表明,融合蛋白不仅具有干扰素的抗病毒、抗增殖、增强NK细胞功能的活性,而且具有脑啡肽的脑内镇痛作用.     

重组人骨形成蛋白-3成熟肽的表达、纯化及诱骨活性的研究*

推测人骨形成蛋白-3羧基端的127氨基酸的肽段为其成熟肽(hRMP 3m)。将编码此成熟肽的cDNA插入含PL启动子的表达质粒pDH中,构建表达质粒pDH-B-3m,转化大肠杆菌DH5α。42℃热诱导6h后表达量达到最高水平,约占菌体总蛋白28％;表达产物以包涵体形式存在。包涵体经分离和洗涤后．溶解于尿素,在变性溶解状态下经阳离子交换层析,目的蛋白纯度至少在95％以上。再经稀释复性。然后将纯化、复性的重组人骨形成蛋白3成熟肽(rhBMP－3m)植入小鼠肌肉间隙,于不同时间取材观察,在局部可见典型的软骨形成、软骨内成骨以及骨组织形成的过程,证实所制备的rhBMP－3m具有明显的异位诱骨活性。     

胶质细胞源性神经营养因子受体α1基因的克隆表达及其活性研究

为了获得重组胶质细胞源性神经营养因子受体α1（glial cell line-derived neurotrophic factor receptor alpha1, GFRα1）并研究其生物学活性,从新生4天的SD大鼠海马组织中提取总RNA,通过 RT-PCR方法,扩增出GFRα1 cDNA.将GFRα1 cDNA克隆至含T7启动子的质粒pET-28a（+）中,构建表达质粒pET-GFRα1,转化大肠杆菌BL21（DE3）,获得表达菌株BLGFRα1.表达菌株经1 mmol/L IPTG诱导3～5 h后,GFRα1蛋白表达,并形成包涵体.凝胶自动扫描分析表明,GFRα1表达量占全菌总蛋白的21.5%,用Ni²⁺-NTA树脂纯化和复性后,纯度达90%以上,复性的重组GFRα1蛋白可显著介导GDNF促PC12细胞的存活和分化作用.     

干扰素-β1b的高效表达、纯化及抗病毒活性研究

IFN-β1b是大肠杆菌产生的17位Cys被Ser替换的人IFN-β的类似物,为了获得高表达,使用了大肠杆菌的偏爱密码子,人工合成了IFN-β-1b基因,插入质粒pBV220中,转化大肠杆菌DH5α.IFN-β1b的制备过程,包括发酵和一系列的纯化步骤.经修饰,IFN-β1b基因在启动子PRPL控制下发酵表达,合成的蛋白质以包涵体的形式存在.培养的细菌经收集、裂解后,将包涵体释放出来,包涵体经含SDS的溶液溶解,DTT还原.纯化过程包括有机溶剂抽提、分子筛层析、脱盐、氧化复性和反相层析,并用旋转蒸发除去有机溶剂.IFN-β-1b在不同种系来源的细胞上显示不同的抗病毒活性.     

乳酸菌素Gassericin T基因的合成及其在大肠杆菌中的融合表达

目的:在大肠杆菌系统中表达有抗菌活性的乳酸菌素Gassericin T。方法:根据乳酸菌素Gassericin T的基因序列,把Gassericin T的结构基因gatA编码的氨基酸的密码子转换成大肠杆菌偏爱的形式;用人工合成的寡核苷酸片段,通过重叠PCR法扩增得到gatA片段(gat基因);将合成的gat基因插入pGEX-4T-1,构建pGEX-4T-1-gat融合表达载体,转化大肠杆菌DH5α株,IPTG诱导表达,经超声裂解后获得包涵体蛋白,经溶解、变性、复性处理后获得GST-Gassericin T融合蛋白;用琼脂扩散法测定其对金黄色葡萄球菌、大肠杆菌、李斯特菌、枯草杆菌等的抗菌活性。结果与结论:采用pGEX-4T-1融合表达系统在大肠杆菌中表达了有活性的Gassericin T,融合蛋白以包涵体形式存在。复性的融合蛋白对金黄色葡萄球菌和大肠杆菌有明显的抑制作用,对李斯特菌的抑制作用不明显。     

猪γ干扰素基因的克隆、表达及其纯化

以RT-PCR方法,从经丝裂原诱导的猪外周血淋巴细胞总RNA中扩增出编码猪IFNγ的基因。经测序证实后插入载体pJLA503,并实现在大肠杆菌中的高表达。表达产物以包涵体形式存在,经7mol/L盐酸胍变性及精氨酸存在的情况下复性。再经DEAE-Sepharose离子交换柱、Sephdex-200凝胶过滤柱分离获得电泳单一纯猪IFN-γ蛋白,细胞病变抑制实验检测纯化产物有干扰素活性。     

抗Her-2-scFv-SEC2融合免疫毒素的构建和功能研究

用基因工程方法,将金黄色葡萄球菌肠毒素 C2 与抗人表皮生长因子受体 HER-2 单链抗体 scFv-B1,以一连接短肽连接,构建融合免疫毒素 B-L-SEC2,并用改进的新型表达载体 pASK75-EX,在大肠杆菌 BL21(ED3)中表达. 以不溶性包涵体形式表达的目的蛋白经变性后以镍离子螯和层析纯化,并以透析法进行复性. 流式细胞术和 MTT 实验结果表明,纯化复性的融合免疫毒素 B-L-SEC2,在体外具有与 HER-2 过表达的靶细胞 SK-Br-3 特异性结合的活性,并对该细胞产生显著的特异性生长抑制作用.     

Factors affecting protein refolding yields in a fed-batch and batch-refolding system

The refolding of recombinant protein from inclusion bodies expressed in Escherichia coli can present a process bottleneck. Yields at industrially relevant concentrations are restricted by aggregation of protein upon dilution of the denatured form. This article studies the effect of five factors upon the dilution refolding of protein in a twin impeller fed-batch system using refold buffer containing only the oxidized form of the redox reagent. Such a buffer is easier to prepare and more stable than a buffer containing both reduced and oxidized forms. The five factors chosen were: bulk impeller Reynolds number, mini-impeller Reynolds number, injection rate of denatured protein, redox ratio, and guanidine hydrochloride (GdHCl) concentration. A 2(5) factorial experiment was conducted at an industrially relevant protein concentration using lysozyme as the test system. The study identified that in the system used, the guanidine hydrochloride concentration, redox ratio, and injection rate were the most important factors in determining refolding yields. Two interactions were found to be important: redox ratio/guanidine hydrochloride concentration and guanidine hydrochloride concentration/injection rate. Conditions were also found at which high refolding yields could be achieved even with rapid injection and poor mixing efficiency. Therefore, a comparative assessment was carried out with minimal mixing in a simple batch-refolding mode of operation, which revealed different behavior to that of fed-batch. A graphical (windows of operation) analysis of the batch data suggested that optimal yields and productivity are obtained at high guanidine hydrochloride concentrations (1.2 M) and redox ratios of unity or greater.     

L-cysteine-enhanced renaturation of bioactive soluble tumor necrosis factor ligand family member LIGHT from inclusion bodies in Escherichia coli

LIGHT is a membrane-bound protein that belongs to the tumor necrosis factor (TNF) superfamily ligands. In this study, we established an effective strategy for producing a bioactive soluble form of LIGHT (sLIGHT), an extracellular region (Ile??-Val2??) of human LIGHT. Because sLIGHT was expressed as inclusion bodies in Escherichia coli, we investigated reagents that enhance the renaturation of sLIGHT from the inclusion bodies. Interestingly, L-cysteine in the denaturation buffer containing 3.5 M guanidine hydrochloride significantly improved the renaturation efficiency of sLIGHT. The effect of L-cysteine was synergistically enhanced by L-arginine in the refolding buffer. The optimal concentrations of L-cysteine and L-arginine in the denaturation and refolding buffers were 8 mM and 0.8 M, respectively. With these buffers, approximately 90 mg of sLIGHT was purified from 200 g of frozen E. coli cells. sLIGHT thus obtained significantly induced apoptosis in the WiDr human colon adenocarcinoma cell line at nanomolar concentrations, the same amount of sLIGHT that was produced by Sf9 insect cells. These results suggest that L-cysteine in the denaturation buffer enhances the renaturation of recombinant proteins from inclusion bodies in E. coli.     

High recovery refolding of rhG-CSF from Escherichia coli, using urea gradient size exclusion chromatography

Protein folding liquid chromatography (PFLC) is a powerful tool for simultaneous refolding and purification of recombinant proteins in inclusion bodies. Urea gradient size exclusion chromatography (SEC) is a recently developed protein refolding method based on the SEC refolding principle. In the presented work, recombinant human granulocyte colony-stimulating factor (rhG-CSF) expressed in Escheriachia coli (E. coli) in the form of inclusion bodies was refolded with high yields by this method. Denatured/reduced rhG-CSF in 8.0 mol.L(-1) urea was directly injected into a Superdex 75 column, and with the running of the linear urea concentration program, urea concentration in the mobile phase and around the denatured rhG-CSF molecules was decreased linearly, and the denatured rhG-CSF was gradually refolded into its native state. Aggregates were greatly suppressed and rhG-CSF was also partially purified during the refolding process. Effects of the length and the final urea concentration of the urea gradient on the refolding yield of rhG-CSF by using urea gradient SEC were investigated respectively. Compared with dilution refolding and normal SEC with a fixed urea concentration in the mobile phase, urea gradient SEC was more efficient for rhG-CSF refolding--in terms of specific bioactivity and mass recovery, the denatured rhG-CSF could be refolded at a larger loading volume, and the aggregates could be suppressed more efficiently. When 500 microL of solubilized and denatured rhG-CSF in 8.0 mol.L(-1) urea solution with a total protein concentration of 2.3 mg.mL(-1) was loaded onto the SEC column, rhG-CSF with a specific bioactivity of 1.0 x 10(8) IU.mg(-1) was obtained, and the mass recovery was 46.1%.     

Production and purification of refolded recombinant human IL-7 from inclusion bodies

A recombinant form of human rhIL-7 was overexpressed in Escherichia coli HMS174 (DE3) pLysS under the control of a T7 promoter. The resulting insoluble inclusion bodies were separated from cellular debris by cross-flow filtration and solubilized by homogenization with 6 M guanidine HCl. Attempts at refolding rhIL-7 from solubilized inclusion bodies without prior purification of monomeric, denatured rhIL-7 were not successful. Denatured, monomeric rhIL-7 was therefore initially purified by size-exclusion chromatography using Prep-Grade Pharmacia Superdex 200. Correctly folded rhIL-7 monomer was generated by statically refolding the denatured protein at a final protein concentration of 80-100 microg/ml in 100 mM Tris, 2mM EDTA, 500 mM L-arginine, pH 9.0, buffer with 0.55 g/l oxidized glutathione at 2-8 degrees C for at least 48 h. The refolded rhIL-7 was subsequently purified by low-pressure liquid chromatography, using a combination of hydrophobic interaction, cation-exchange, and size-exclusion chromatography. The purified final product was >95% pure by SDS-PAGE stained with Coomassie brilliant blue, high-pressure size-exclusion chromatography (SEC-HPLC), and reverse-phase HPLC. The endotoxin level was <0.05 EU/mg. The final purified product was biologically active in a validated IL-7 dependent pre-B-cell bioassay. In anticipation of human clinical trials, this material is currently being evaluated for safety and efficacy in non-human primate toxicology studies.     

一种新的Bt杀虫基因HJC原核表达蛋白活性的鉴定

HJC基因是由2个Bt基因(cry1Ab和vip3)经过人工融合而成,具有更广谱的杀虫活性,可延缓害虫产生交互抗性的时间。将已构建好的携带HJC基因的重组质粒pET28a-HJC转化到大肠杆菌BL21中诱导表达。该HJC融合蛋白主要以包涵体形式存在,变性条件下使用镍亲和层析柱对其进行纯化,并经尿素梯度透析复性后,进行免疫反应活性及美国白蛾杀虫活性测定。Western blot结果显示,该原核表达蛋白与转HJC基因水稻中的HJC蛋白有相同的免疫反应性,对美国白蛾也有一定的杀虫活性,可以替代植物外源蛋白进行转HJC基因产品的食用安全性评价。     

人骨形成蛋白-2C端102肽的诱骨活性

为分析更短的Hbmp-2C端肽是否具有诱骨活性 ,寻求新型的有诱骨活性的基因工程Hbmp-2产品。利用温度诱导的大肠杆菌表达系统表达肽段长度为102个氨基酸的Hbmp-2C端肽及其Cys的突变体。表达产物经纯化复性后 ,植入小鼠肌袋模型中测试其诱骨活性。获得了能稳定表达Hbmp 2C端肽的工程菌 ,测序结果与预期的序列完全一致。表达产物以包涵体形式存在 ,表达量占细胞总蛋白的 3 0 %。产物经纯化复性后 ,小鼠肌袋模型测试结果表明 :Hbmp 2 10 2肽仍具有诱骨活性 ,而将C端第一位Cys突变的 10 2肽诱骨活性丧失。实验表明 :比Hbmp 2成熟肽 ( 114个氨基酸 )更短的C端 10 2肽仍具有良好诱骨活性 ,这 10 2肽N端第一个Cys对其诱骨活性可能是必需的。     

Expression and purification of milligram levels of inactive G-protein coupled receptors in E. coli

G-protein coupled receptors (GPCRs) are seven transmembrane helical proteins involved in cell signaling and response. They are targets for many existing therapeutic agents, and numerous drug discovery efforts. Production of large quantities of these receptors for drug screening and structural biology remains challenging. To address this difficulty, we sought to express genes for several human GPCRs in Escherichia coli. For most of the receptors, expression was poor, and was not markedly improved even in strains designed to compensate for differences in codon bias between human and E. coli genes. However, the gene for human NK(1) receptor (hNK(1)R) was expressed in large quantities as inclusion bodies in E. coli. The inclusion bodies were not soluble in chemical denaturants such as guanidine chloride or urea, but were soluble in ionic detergents such as SDS, and the zwitterionic detergent fos-choline. Using immobilized metal affinity chromatography, we purified milligram amounts of hNK(1)R. Although inactive in ligand-binding assays, purified hNK(1)R in fos-choline micelles appeared to have a high content of alpha-helix, and was well-behaved in solution. Thus this protein is suitable for additional biophysical characterization and refolding studies.     

N-糖酰胺酶F在大肠杆菌中的高效表达及其脱糖基化作用研究

从脑膜炎脓杆菌（Flavobacterium meningosepticum）基因组中通过PCR扩增了N-糖酰胺酶F（PNGase F）基因,经酶切后与表达载体pET28a连接,获得的重组质粒转入大肠杆菌BL21(DE3)。重组大肠杆菌经诱导表达和纯化提取后,获取大量高纯度N-糖酰胺酶F,其纯度达90%以上。试验证明,经纯化的重组N-糖酰胺酶F可以切除核糖核酸酶B、转铁蛋白和人IgG等糖蛋白上的N-糖链,具有脱糖基化作用。